Skip to main content

Table 1 Baseline cohort characteristics

From: A validation study of crescents in predicting ESRD in patients with IgA nephropathy

Variables

Overall

C0

C1

C2

(n = 1152)

(n = 619)

(n = 447)

(n = 86)

Follow-up (months)

45 (25–70)

45 (24–70)

43 (26–68)

59 (27–88)

eGFR decline rate (ml/min/1.73 m2/year)

− 1.1 (− 4.6 to − 1.8)

− 1.2 (− 4.6 to − 1.6)

− 1.0 (− 4.3 to − 2.0)

− 0.25 (− 4.6 to − 3.43)

Male (%)

566 (49.1)

304 (49.1)

221 (49.4)

41 (47.7)

Age (years)

35.4 ± 12.0

36.5 ± 12.1

34.3 ± 11.9*

33.0 ± 10.6*

Urinary protein (g/d)

1.42 (0.72–2.62)

1.19 (0.62–2.39)

1.44 (0.82–2.71)*

2.51 (1.62–3.99)**

eGFR (ml/min/1.73 m2)

79.12 (52.08–101.67)

78.46 (48.37–103.41)

81.67 (56.59–100.82)

65.95 (47.11–91.95)*

Hypertension (%)

381 (33.1)

217 (35.1)

134 (30.0)

30 (34.9)

MAP (mmHg)

95.8 ± 13.5

96.2 ± 13.3

94.9 ± 13.3

97.6 ± 16.2

Oxford classification

 M1 (%)

469/1089 (43.1)

208/586 (35.5)

217/425 (51.1)**

44/78 (56.4)**

 E1 (%)

459/1089 (42.1)

157/586 (26.8)

239/425 (56.2)**

63/78 (80.8)**

 S1 (%)

839/1089 (77.0)

422/586 (72.0)

363/425 (85.4)**

54/78 (69.2)

 T1 + T2 (%)

364/1089 (33.4)

195/586 (33.3)

133/425 (31.3)

36/78 (46.2)*

With immunosuppression (%)

566/1078 (52.5)

288/578 (49.8)

210/416 (50.5)

68/84 (81.0)**

  1. ESRD end stage renal disease, eGFR estimated glomerular filtration rate, MAP mean arterial pressure
  2. * P < 0.05 and ** P < 0.001 compared to the C0 group